

From Lipids to Signalling: Herbal Formulation Strategies in Type 2 Diabetes Mellitus with Emphasis on *Andrographis paniculata* Hard Gelatin Capsules

R Priyadharshini^{*1}, I Kevin¹, A Kalaiyarasan¹, B Vishwa¹, K Vishwa¹

1.Department of Pharmaceutics, RVS College of Pharmaceutical Sciences, Coimbatore, Tamil Nadu, Affiliated to The Tamil Nadu Dr MGR Medical University, Guindy, Chennai-600032, Tamil Nadu, India.

ABSTRACT:

Insulin resistance and relative insulin insufficiency are the main causes of type 2 diabetes mellitus (T2DM), a chronic metabolic disease marked by persistent hyperglycemia. T2DM is becoming more and more common worldwide, which presents a serious public health concern. Chronic low-grade inflammation, oxidative stress, disrupted insulin signalling pathways, and altered lipid metabolism are all strongly associated with insulin resistance. The fundamental pathophysiology of insulin resistance is not sufficiently addressed by traditional antidiabetic medications, despite their effectiveness in glycaemic management and frequent side effects. Due to their long history of traditional usage, improved tolerability, and multitargeted activities, herbal medications have drawn more attention in recent years. The well-known medicinal herb *Andrographis paniculata* has shown notable antihyperlipidemic, antidiabetic, antioxidant, and insulin-sensitizing effects. This article offers a thorough analysis of type 2 diabetes, including its etiology, contemporary treatment modalities, and the function of herbal remedies in antidiabetic treatment. With particular reference to hard gelatin capsules, special attention is paid to *Andrographis paniculata*, its phytochemistry, pharmacological activity, and formulation issues. The improvement of insulin sensitivity in diabetes is highlighted in the essential discussion of the molecular relationship among lipid metabolism, insulin signalling, and glycaemic control. Lastly, a summary of current research gaps and potential directions for herbal antidiabetic formulations is provided.

Keywords: Type 2 diabetes mellitus, insulin resistance, insulin sensitivity, lipid metabolism, *Andrographis paniculata*, herbal formulations, hard gelatin capsules.

INTRODUCTION:

A class of metabolic diseases known as diabetes mellitus is typified by persistently high blood sugar levels brought on by deficiencies in either insulin production, insulin action, or both (1). Type 2 diabetes mellitus makes up between 90 and 95 percent of all cases of diabetes globally. Obesity, a sedentary lifestyle, dyslipidemia, and genetic risk are all closely linked to the condition (2). A defining feature of type 2 diabetes, insulin resistance is essential to the advancement of the illness and the emergence of chronic complications. (3)

Recent scientific attention has shifted from mere glycaemic control to improving insulin sensitivity and correcting metabolic dysfunctions at the cellular level. (4) Altered lipid metabolism and impaired insulin signalling pathways are now recognized as key contributors to insulin resistance. (5) Herbal medicines, with their complex mixture of bioactive compounds, offer a promising approach to target multiple pathways simultaneously (6).

Traditional medical systems have made extensive use of *Andrographis paniculata*, sometimes referred to as "Kalmegh," to treat diabetes and other metabolic diseases (7). Its main bioactive component, andrographolide, has demonstrated promise in regulating lipid metabolism, boosting insulin sensitivity, and promoting glycaemic management (8). Using a formulation-oriented viewpoint, this study critically examines *A. paniculata*'s therapeutic potential in T2DM.

TYPE 2 DIABETES MELLITUS: DEFINITION, CLASSIFICATION AND EPIDEMIOLOGY

Chronic hyperglycemia brought on by insulin resistance and insufficient compensatory insulin production is the hallmark of type 2 diabetes mellitus, a metabolic disease (9). Unlike type 1 diabetes, type 2 diabetes develops gradually over time rather than being largely caused by the autoimmune loss of pancreatic β -cells.(10) Type 1 diabetes mellitus, type 2 diabetes mellitus, gestational diabetes mellitus, and other distinct forms linked to genetic flaws, pancreatic disorders, or drug-induced illnesses are the main categories of diabetes mellitus. The most common of them is type 2 diabetes, which is greatly impacted by lifestyle choice (11).

The prevalence of type 2 diabetes is rapidly rising, according to epidemiological data, especially in emerging nations. This tendency has been greatly influenced by urbanization, dietary changes, physical inactivity, and rising obesity rates (12). With a significant percentage of people acquiring diabetes at an earlier age, India is regarded as one of the world's epicenters for the condition. The growing prevalence of type 2 diabetes highlights the pressing need for more comprehensive, affordable, and safe treatment approaches (13).

PATHOPHYSIOLOGY OF TYPE 2 DIABETES MELLITUS

T2DM has a complicated and diverse etiology. A major problem is insulin resistance in peripheral tissues such the liver, adipose tissue, and skeletal muscle. Pancreatic β -cells make up for this in the early stages of the illness by secreting more insulin. Prolonged metabolic stress, however, ultimately results in β cell failure and malfunction (14).

The development of insulin resistance is significantly influenced by altered lipid metabolism. Impaired glucose uptake results from disruptions in insulin signalling pathways caused by elevated free fatty acids and ectopic lipid buildup (15). Oxidative stress and persistent inflammation also make insulin resistance worse.

Reduced phosphorylation of insulin receptor substrates, malfunctions in insulin receptor signalling, and poor activation of downstream pathways like PI3K/Akt are some of the biochemical causes of diminished insulin sensitivity. These alterations result in reduced glucose transporter translocation and increased hepatic glucose production, culminating in persistent hyperglycaemia (16).

CURRENT THERAPEUTIC APPROACHES FOR TYPE 2 DIABETES MELLITUS

The management of T2DM primarily aims at achieving and maintaining optimal glycaemic control while preventing complications. Lifestyle modification, including dietary regulation and physical activity, forms the cornerstone of therapy (17). Pharmacological treatment includes oral hypoglycaemic agents and injectable therapies.

Biguanides, sulfonylureas, thiazolidinediones, DPP 4 inhibitors, SGLT-2 inhibitors, and GLP-1 receptor agonists are among the frequently utilized medication classes (18). Despite the fact that these medications effectively lower blood glucose levels, many of them have negative side effects, including weight gain, hypoglycemia, gastrointestinal issues, and cardiovascular

Moreover, most conventional therapies focus on symptomatic control rather than addressing the underlying insulin resistance. This limitation has led to growing interest in alternative and complementary therapies, particularly herbal medicines with insulin sensitizing properties. (20)

HERBAL MEDICINES IN ANTIDIABETIC THERAPY

In management of diabetes Herbal medicines are used in the centuries. Numerous medicinal plants possess antihyperglycaemic, antihyperlipidaemic, antioxidant, and anti-inflammatory activities (21). The multitargeted nature of herbal drugs makes them particularly suitable for complex metabolic disorders like T2DM.

Among the many ways that herbal antidiabetic medicines work is by promoting insulin production, improving insulin sensitivity, blocking enzymes that break down carbohydrates, modifying lipid metabolism, and shielding pancreatic β -cells (22). Additionally, their relatively lower toxicity and better patient compliance make them attractive alternatives or adjuncts to conventional therapy (23).

However, lack of standardization, variability in phytochemical content, and limited clinical evidence remain major challenges in the widespread acceptance of herbal medicines (24).

***Andrographis paniculata*: Botanical and Phytochemical Profile**

The annual herb *Andrographis paniculata* is a member of the Acanthaceae family. It is widely distributed in tropical and subtropical regions and is extensively used in traditional medicine systems (25).

Diterpenoid lactones, flavonoids, polyphenols, and sterols have all been found through phytochemical analyses. The primary bioactive substance in charge of the majority of the plant's pharmacological actions is andrographolide (26). Other important constituents include deoxyandrographolide and neoandrographolide (27).

PHARMACOLOGICAL ACTIVITIES RELEVANT TO DIABETES

A. paniculata has been shown to have antidiabetic properties in a number of preclinical investigations (28). It has been demonstrated that the plant extracts and isolated components increase insulin sensitivity, improve glucose tolerance, and lower fasting blood glucose levels (29).

Improving insulin resistance is largely dependent on *A. paniculata*'s antihyperlipidaemic action. Improved insulin signalling is a result of lower levels of total cholesterol, free fatty acids, and serum triglycerides (30).

Anti-inflammatory effects further support the role of *A. paniculata* in improving metabolic health, as chronic inflammation is a key contributor to insulin resistance in T2DM (31).

ENHANCEMENT OF INSULIN SENSITIVITY IN DIABETES

Enhancement of insulin sensitivity is a primary therapeutic goal in the management of T2DM. Increased insulin sensitivity lowers hepatic glucose production and promotes effective glucose absorption by peripheral tissues (32).

Herbal agents such as *A. paniculata* enhance insulin sensitivity by modulating insulin receptor signalling pathways, activating AMP-activated protein kinase, and improving lipid metabolism. By reducing lipid-induced insulin resistance and oxidative stress, these agents restore insulin responsiveness at the cellular level (33).

In addition to helping with glycaemic management, increased insulin sensitivity lowers the risk of cardiovascular problems linked to type 2 diabetes.

MECHANISTIC LINK: LIPID METABOLISM, INSULIN SIGNALLING AND GLYCAEMIC CONTROL

Lipid metabolism and insulin signalling are intricately connected. Excess circulating lipids impair insulin signalling through lipotoxicity, leading to reduced glucose uptake. Dysregulated lipid metabolism also promotes inflammation and oxidative stress, further worsening insulin resistance (34).

Herbal compounds that modulate lipid metabolism can indirectly improve insulin signalling and glycaemic control. It has been demonstrated that *A. paniculata* improves insulin receptor activity, increases fatty acid oxidation, and decreases lipid buildup (35).

By targeting the lipid-insulin axis, herbal formulations offer a comprehensive approach to managing T2DM beyond conventional glucose-lowering strategies (36).

FORMULATION ASPECTS OF HERBAL ANTIDIABETIC PRODUCTS

Formulation plays as an Important part in the efficacy and stability of herbal medicines. Challenges such as poor solubility, low bioavailability, and variability in phytochemical content must be addressed to ensure therapeutic effectiveness (37)

Hard gelatin capsules are widely used for herbal formulations due to their convenience, accurate dosing, and patient acceptability (38). They provide protection to active constituents from environmental factors and allow incorporation of standardized extracts.

For *A. paniculata*, formulation into hard gelatin capsules ensures uniform distribution of andrographolide, improved stability, and enhanced bioavailability. Excipients such as diluents, disintegrants, and glidants are selected to optimize release characteristics (39).

Andrographis paniculata Hard Gelatin Capsules: Therapeutic Rationale

The use of *A. paniculata* in hard gelatin capsule form offers several advantages. Standardization of extracts ensures consistent therapeutic outcomes, while encapsulation improves patient compliance (40).

Such formulations can be developed as standalone therapies or as adjuncts to conventional antidiabetic drugs (41). The combination of insulin-sensitizing, lipid lowering, and antioxidant effects makes *A. paniculata* capsules particularly suitable for long-term management of T2DM (42).

RESEARCH GAPS AND FUTURE PERSPECTIVES

Despite promising preclinical evidence, clinical validation of *A. paniculata* formulations remains limited. Large-scale, well-designed clinical trials are required to establish efficacy, safety, and optimal dosing (43).

Standardization of herbal extracts, quality control, and regulatory approval are critical challenges. Future research should focus on advanced drug delivery systems, pharmacokinetic studies, and mechanistic investigations to full exploit the therapeutic potential of *A. paniculata* (44).

CONCLUSION

Insulin resistance and dysregulated lipid metabolism are the main causes of type 2 diabetes mellitus, a complicated metabolic disease. Enhancing insulin sensitivity represents a rational and effective therapeutic strategy. Herbal medicines, particularly *Andrographis paniculata*, offer a promising multitargeted approach to T2DM management.

Formulation of *A. paniculata* into hard gelatin capsules provides a practical and effective dosage form with improved stability and patient compliance. By modulating lipid metabolism, insulin signalling, and glycaemic control, such herbal formulations hold significant potential as adjunct or alternative therapies in T2DM. To incorporate these advantages into standard therapeutic practice, more study and clinical confirmation are required.

REFERENCE

1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. *Diabetes care*. 2013 Jan 1;36(Supplement_1):S67-74.
2. Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. *Nature reviews endocrinology*. 2018 Feb;14(2):88-98.
3. Zhao X, An X, Yang C, Sun W, Ji H, Lian F. The crucial role and mechanism of insulin resistance in metabolic disease. *Frontiers in endocrinology*. 2023 Mar 28;14:1149239.
4. Bolt T. A Global Epidemic of What? A Century of Debate About the Rising Rates of Diabetes and How it is Relevant Today. *European Journal for the History of Medicine and Health*. 2025 Apr 30;1(aop):1-47.
5. Savage DB, Petersen KF, Shulman GI. Disordered lipid metabolism and the pathogenesis of insulin resistance. *Physiological reviews*. 2007 Apr;87(2):507-20.
6. Long F, Yang H, Xu Y, Hao H, Li P. A strategy for the identification of combinatorial bioactive compounds contributing to the holistic effect of herbal medicines. *Scientific reports*. 2015 Jul 22;5(1):12361.
7. Mishra SK, Sangwan NS, Sangwan RS. Phcog rev.: Plant review *Andrographis paniculata* (Kalmegh): A review. *Pharmacognosy Reviews*. 2007 Jul;1(2):283-98.
8. Dai Y, Chen SR, Chai L, Zhao J, Wang Y, Wang Y. Overview of pharmacological activities of *Andrographis paniculata* and its major compound andrographolide. *Critical reviews in food science and nutrition*. 2019 Jun 27;59(sup1):S17-29.
9. Nolan CJ, Prentki M. Insulin resistance and insulin hypersecretion in the metabolic syndrome and type 2 diabetes: Time for a conceptual framework shift. *Diabetes and Vascular Disease Research*. 2019 Mar;16(2):118-27.
10. Eizirik DL, Pasquali L, Cnop M. Pancreatic β -cells in type 1 and type 2 diabetes mellitus: different pathways to failure. *Nature Reviews Endocrinology*. 2020 Jul;16(7):349-62.
11. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. *Diabetic medicine*. 1998 Jul;15(7):539-53.
12. Oggioni C, Lara J, Wells JC, Soroka K, Siervo M. Shifts in population dietary patterns and physical inactivity as determinants of global trends in the prevalence of diabetes: an ecological analysis. *Nutrition, Metabolism and Cardiovascular Diseases*. 2014 Oct 1;24(10):1105-11.
13. Maheshwari A, Viswanathan V SA. Diabetes care in rural India—review. *J Diabetes Metab Disord Control*. 2025;12(1):42-7.
14. Rattarasarn C. Physiological and pathophysiological regulation of regional adipose tissue in the development of insulin resistance and type 2 diabetes. *Acta Physiologica*. 2006 Feb;186(2):87-101.
15. Li M, Chi X, Wang Y, Setrerrahmane S, Xie W, Xu H. Trends in insulin resistance: insights into mechanisms and therapeutic strategy. *Signal transduction and targeted therapy*. 2022 Jul 6;7(1):216.
16. Ramasubbu K, Devi Rajeswari V. Impairment of insulin signalling pathway PI3K/Akt/mTOR and insulin resistance induced AGEs on diabetes mellitus and neurodegenerative diseases: a perspective review. *Molecular and Cellular Biochemistry*. 2023 Jun;478(6):1307-24.
17. Agede OA. Pharmacotherapy of Type 2 Diabetes Mellitus (T2DM) in Clinical Practice: a comprehensive review of the treatment options. *Nigerian Stethoscope*. 2024 Dec 23;6(2):8-18.
18. Liakos CI, Papadopoulos DP, Sanidas EA, Markou MI, Hatzigelaki EE, Grassos CA, Velliou ML, Barbetseas JD. Blood pressure-lowering effect of newer antihyperglycemic agents (SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors). *American Journal of Cardiovascular Drugs*. 2021 Mar;21(2):123-37.
19. Kalyani RR. Glucose-lowering drugs to reduce cardiovascular risk in type 2 diabetes. *New England Journal of Medicine*. 2021 Apr 1;384(13):1248-60.
20. Prasad M, Jayaraman S, Eladl MA, El-Sherbiny M, Abdelrahman MA, Veeraraghavan VP, Vengadassalpathy S, Umamathy VR, Jaffer Hussain SF, Krishnamoorthy K, Sekar D. A comprehensive review on therapeutic perspectives of phytosterols in insulin resistance: a mechanistic approach. *Molecules*. 2022 Feb 28;27(5):1595.
21. Tran N, Pham B, Le L. Bioactive compounds in anti-diabetic plants: From herbal medicine to modern drug discovery. *Biology*. 2020 Aug 28;9(9):252.

22. Chahrour JA, Abdel Baki Z, El Badan D, Nasser G, Maresca M, Hijazi A. Herbal Medicines in the Management of Diabetes Mellitus: Plants, Bioactive Compounds, and Mechanisms of Action. *Biomolecules*. 2025 Dec 1;15(12):1674.
23. Cassileth BR. Evaluating complementary and alternative therapies for cancer patients. *CA: a cancer journal for clinicians*. 1999 Nov;49(6):362-75.
24. Dhami N, Mishra AD. Phytochemical variation: how to resolve the quality controversies of herbal medicinal products?. *Journal of herbal medicine*. 2015 Jun 1;5(2):118-27.
25. Yadav PB, Karuppusamy S. Botany of *Andrographis* Wall. ex Nees (*Andrographinae*: *Acanthaceae*). In *Andrographolide and its Analogs: Botanical Sources, Phytochemistry, Pharmacology, and Biotechnology* 2024 Dec 19 (pp. 10-29). Bentham Science Publishers.
26. Avula B, Katragunta K, Tatapudi KK, Wang YH, Ali Z, Chittiboyina AG, Khan IA. Phytochemical analysis of phenolics and diterpene lactones in *Andrographis paniculata* plant samples and dietary supplements. *Journal of Pharmaceutical and Biomedical Analysis*. 2025 Sep 1;262:116866.
27. Rajagopal VP, Jayaraman S. Studies on Anti-inflammatory and Anti-diabetic Potential of *Andrographolide*: Evidence from an In vitro, In silico and In vivo Study.
28. Komalasari T, Harimurti S. A Review on the Anti-diabetic Activity of *Andrographis paniculata* (Burm. f.) Nees based In-vivo Study. *Int J Public Heal Sci*. 2015 Dec;4(4):256-63.
29. Eddouks M, Bidi A, El Bouhali B, Hajji L, Zeggwagh NA. Antidiabetic plants improving insulin sensitivity. *Journal of Pharmacy and Pharmacology*. 2014 Sep;66(9):1197-214.
30. Chen CC, Lii CK, Lin YH, Shie PH, Yang YC, Huang CS, Chen HW. *Andrographis paniculata* improves insulin resistance in high-fat diet-induced obese mice and TNF α -treated 3T3-L1 adipocytes. *The American journal of Chinese medicine*. 2020 Jul 1;48(05):1073-90.
31. Chen CC, Lii CK, Lin YH, Shie PH, Yang YC, Huang CS, Chen HW. *Andrographis paniculata* improves insulin resistance in high-fat diet-induced obese mice and TNF α -treated 3T3-L1 adipocytes. *The American journal of Chinese medicine*. 2020 Jul 1;48(05):1073-90.
32. Home PD, Pacini G. Hepatic dysfunction and insulin insensitivity in type 2 diabetes mellitus: a critical target for insulin-sensitizing agents. *Diabetes, Obesity and Metabolism*. 2008 Sep;10(9):699-718.
33. Sobczyński J, Nowaczyński F, Smolińska K, Lachowicz-Radulska J, Serefko A, Szopa A. Natural Bioactive Compounds Targeting FABP4 in Adipogenesis and Obesity: Evidence from In Vitro and In Vivo Studies. *International Journal of Molecular Sciences*. 2026 Jan 28;27(3):1306.
34. Cao X, Wang N, Yang M, Zhang C. Lipid accumulation and insulin resistance: Bridging metabolic dysfunction-associated fatty liver disease and chronic kidney disease. *International journal of molecular sciences*. 2025 Jul 20;26(14):6962.
35. Karunaratna AM, Ekanayake S. Effect of Herbal Medicine on Insulin Signaling Pathways and Insulin Resistance in Metabolic Dysfunction-associated Fatty Liver Disease: A Review. *The Natural Products Journal*. 2025 May;15(4):E040624230641
36. Wang Y. *The effect of combinatory dietary fibers on the gut microbiota and human gastrointestinal health* (Doctoral dissertation, Rutgers the State University of New Jersey, School of Graduate Studies).
37. Thakur L, Ghodasra U, Patel N, Dabhi M. Novel approaches for stability improvement in natural medicines. *Pharmacognosy reviews*. 2011 Jan;5(9):48.
38. Arangio M, Luftensteiner C. Therapeutic effects and the advantages of soft capsules as appropriate dosage form.
39. Raman S, Murugaiyah V, Parumasivam T. *Andrographis paniculata* dosage forms and advances in nanoparticulate delivery systems: An overview. *Molecules*. 2022 Sep 20;27(19):6164.
40. Rashid R, Kumar S, Mirza AA, Bhat BA. Herbal Formulation Development and Standardization. In *Herbal Pharmacopeia* (pp. 166-187). CRC Press.
41. Dewanjee S, Chakraborty P, Mukherjee B, De Feo V. Plant-based antidiabetic nanoformulations: the emerging paradigm for effective therapy. *International journal of molecular sciences*. 2020 Mar 23;21(6):2217.
42. Dinesh S, Sharma S, Chourasiya R. Therapeutic applications of plant and nutraceutical-based compounds for the management of type 2 diabetes mellitus: a narrative review. *Current Diabetes Reviews*. 2024 Feb 1;20(2):112-30.
43. Chidambaram K. Antiviral efficacy of *Andrographis paniculata* and *andrographolides*: A narrative review. *Asian Pacific Journal of Tropical Biomedicine*. 2024 Nov 1;14(11):461-76.
44. Standardization of herbal extracts, quality control, and regulatory approval are critical challenges. Future research should focus on advanced drug delivery systems, pharmacokinetic studies, and mechanistic investigations to fully exploit the therapeutic potential of *A. paniculata*.

Copyright & License:



© Authors retain the copyright of this article. This work is published under the Creative Commons Attribution 4.0 International License (CC BY 4.0), permitting unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.